Skip to content
Triangle logo TriangleGet started
← Study library

NCT00064337 · REGISTRY CONDITION SEARCH

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2018-08-09

RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloidosis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Hematologic Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * At least 1 of the following diagnoses: * Multiple myeloma * Stage II or III disease * At least 1 of the following must be present: * Serum M-protein of IgG, IgA, IgD, IgE greater than 1.0 g/dL * Urinary M-protein (Bence-Jones) at least 200 mg/24 hours * No IgM peaks except in patients who have physiologic criteria to support a diagnosis of multiple myeloma (e.g., bony lesions, myeloma kidney-cast nephropathy, absence of adenopathy \[unless pathology-proven to be plasma cell infiltration\]) * No monoclonal gammopathy of undetermined significance * No indolent or smoldering myeloma * No disease progression on prior thalidomide or dexamethasone * Histologically confirmed primary systemic amyloidosis * No senile, secondary, localized, dialysis-related, or familial amyloidosis * No severe cardiac involvement * No pre-exertional syncope, ventricular arrhythmia, or symptomatic pleural effusions associated with cardiac involvement * Light Chain Deposition Disease alone or in combination with multiple myeloma meeting the following criteria: * Deposition of granular material containing free light chains/immunoglobulins that did not bind Congo red * Evidence of plasma cell dyscrasia (i.e., monoclonal gammopathy in the serum or urine by immunofixation electrophoresis and/or clonal plasmacytosis) on bone marrow biopsy by immunohistochemistry and/or elevated serum-free light chain concentration * Must have been diagnosed within the past year * Concurrent enrollment in the myeloma repository protocol SWOG-S0309 must be offered PATIENT CHARACTERISTICS: Age * 18 and over (patients with amyloidosis only OR patients with amyloidosis and multiple myeloma OR patients with multiple myeloma only with poor renal function) OR * 70 and over (patients with multiple myeloma only with or without poor renal function) Performance status * Zubrod 0-2 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 2.5 times upper limit of normal (ULN) * SGOT or SGPT no greater than 2.5 times ULN Renal * No hemodialysis within 2 hours of melphalan or stem cell infusion Cardiovascular * See Disease Characteristics * Hemodynamically stable (i.e., systolic blood pressure \> 90 mm Hg in a lying position within the past 42 days) * No myocardial infarction within the past 6 months * No congestive heart failure * No arrhythmia refractory to medical therapy * LVEF greater than 45% by echocardiogram or MUGA Pulmonary * See Disease Characteristics * No history of chronic obstructive or chronic restrictive pulmonary disease * Pulmonary function studies (e.g., FEV\_1 and FVC) at least 50% of predicted * DLCO at least 50% of predicted * Normal high resolution CT scan of the chest and acceptable arterial blood gases (i.e., PO\_2 greater than 70) required for patients unable to complete pulmonary function tests due to bone pain or fracture Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Multiple myeloma patients receiving thalidomide must use 2 methods of effective contraception for at least 4 weeks before, during, and for at least 4 weeks after discontinuation of thalidomide * HIV negative * No other concurrent significant medical condition * No concurrent uncontrolled life-threatening infection * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * See Disease Characteristics * Prior cumulative melphalan dose no more than 200 mg * No other concurrent chemotherapy Endocrine therapy * See Disease Characteristics * No concurrent hormonal therapy Radiotherapy * No concurrent radiotherapy Surgery * Not specified Other * Recovered from prior therapy * Prior or concurrent bisphosphonates allowed
healthy Volunteers
false
maximum Age
120 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70. Mobilization and SC Collection: MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis. Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection). Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \>/= 3.5 x 10\^6 CD34+ cells/kg IV Day 0. Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year.
    intervention Names
    1. Biological: filgrastim
    2. Drug: cyclophosphamide
    3. Drug: dexamethasone
    4. Drug: melphalan
    5. Drug: thalidomide
    6. Procedure: peripheral blood stem cell transplantation
    label
    Treatment
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment
    name
    filgrastim
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment
    name
    cyclophosphamide
    type
    DRUG
  3. arm Group Labels
    1. Treatment
    name
    dexamethasone
    type
    DRUG
  4. arm Group Labels
    1. Treatment
    name
    melphalan
    type
    DRUG
  5. arm Group Labels
    1. Treatment
    name
    thalidomide
    type
    DRUG
  6. arm Group Labels
    1. Treatment
    name
    peripheral blood stem cell transplantation
    type
    PROCEDURE
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
104
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Time from initial registration until death or date of last contact, whichever occurs first, for up to 5 years from the date of the last patient registration.
    measure
    Overall Survival
    time Frame
    5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years
secondary Outcomes
  1. measure
    Hematologic Response
    time Frame
    Until off study
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloidosis.
detailed Description
OBJECTIVES: * Determine overall survival of patients with high-risk multiple myeloma, primary systemic amyloidosis, or light chain deposition disease treated with two courses of modified high-dose melphalan and autologous peripheral blood stem cell transplantation. * Determine the hematologic response in patients treated with this regimen. * Determine the qualitative and quantitative toxic effects of this regimen in these patients. * Determine the prognostic significance of cytogenetic markers in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to disease (high-risk multiple myeloma vs primary systemic amyloidosis vs both). * Induction therapy (multiple myeloma patients only): Patients receive oral dexamethasone on days 1-4, 9-12, and 17-20 and oral thalidomide daily on days 1-35. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity. * Mobilization and stem cell collection: * Multiple myeloma patients: Within 28-35 days after completion of induction therapy, patients receive cyclophosphamide IV over 2-3 hours on day 1 and filgrastim (G-CSF) subcutaneously (SC) daily beginning on day 2 and continuing through the day before the last leukapheresis. Usage of mesna IV on day 1 (prior to and twice after cyclophosphamide administration is recommended). * Primary systemic amyloidosis patients: Patients receive G-CSF SC daily beginning on day 1 and continuing through the day before the last leukapheresis. All patients undergo leukapheresis for the collection of stem cells until the target number of CD34+ cells is reached. * Conditioning regimen: Within 1-4 weeks after mobilization, patients receive modified high-dose melphalan IV over 20 minutes on day -2. * Peripheral blood stem cell (PBSC) reinfusion: PBSCs are reinfused on day 0. Patients receive G-CSF SC daily beginning on day 1 and continuing until blood counts recover. Patients undergo a second autologous PBSC transplantation within 3-6 months, but no later than 12 months, after the first transplantation. * Second conditioning regimen: Patients receive modified high-dose melphalan IV over 20 minutes on day -2. * Second PBSC infusion: PBSCs are infused on day 0. * Maintenance regimen (multiple myeloma patients only): Between 4-8 weeks after the second transplantation, patients with no progressive disease receive oral dexamethasone once daily on days 1-4 and oral thalidomide once daily on days 1-28. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 and 6 months and then annually thereafter. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 20-25 months.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0df520788fc58dfd3782
      requested nct id
      NCT00064337
      primary nct id
      NCT00064337
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      854db9697436672268c5400795309aeeeb3dd3de828db07e91075ea52a9f525a
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0df520788fc58dfd3782
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00064337
      occurrences
      1. context exact
        NCT00064337
        end
        11
        exact text
        NCT00064337
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/923/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      eb1589bf432b738e787685ade90499df80bf492ba969e1a3b051b3e0f94580c5

    Preserved source evidence · Not medical advice